Delivers stronger recent returns (57.2% 1-year) with concentrated pharmaceutical exposure, but carries higher expense ratio (0.35%), lower dividend yield (0.5%), and significantly higher volatility (max drawdown -30.9%), making it suitable only for growth-focused investors with higher risk tolerance.
Delivered stronger 1-year returns (63.90%) and lower volatility (max drawdown -31.60% vs -38.00%), but higher expense ratio (0.35%), more concentrated portfolio (65 holdings), and positioned as a more targeted bet for investors with specific pharmaceutical sector conviction.
XPH provides broader diversification with 65 holdings, lower historical volatility (beta 0.79, max drawdown -34.99%), and significantly higher 1-year returns (64.30%). The article recommends it for beginners seeking stability and diversity in the pharmaceutical sector.
Recommended as the better choice due to lower expense ratio (0.35%), higher 1-year return (38%), dividend payout (0.70% yield), and better long-term value for cost-conscious investors.
Articles that tag XPH but are mainly about other companies.
AMRX is a component of this pharmaceutical sector ETF. The ETF showed +1.88% movement, which reflects broader sector performance rather than being driven solely by AMRX's acquisition announcement.
Mentioned as a fund holding PBH. Similar to SAEF, it carries PBH with significant weight, but no specific directional impact is indicated in the article.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology